

To: Office of Attorney General

AGO.highcostprescriptiondrugs@vermont.gov

From: Mylan Institutional Inc.

1000 Mylan Boulevard

Canonsburg, Pennsylvania 15317

Date: August 26, 2019

Re: 18 V.S.A § 4637

In compliance with 18 V.S.A. § 4637, Mylan Institutional Inc. hereby provides written notice that on August 23, 2019 it introduced the following new generic prescription drug to market:

Hydroxyprogesterone Caproate 250mg/mL 1mL Injection 1PK